You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK):小分子創新藥HLX99的臨牀試驗申請獲美國食品藥品管理局(FDA)批准
格隆匯 02-10 17:39

格隆匯2月10日丨復宏漢霖(02696.HK)發佈公吿,近日,公司自主研發的小分子創新藥HLX99(“HLX99”)的臨牀試驗申請獲美國食品藥品管理局(FDA)批准。 HLX99擬用於治療肌萎縮側索硬化(ALS)。

HLX99是公司自主研發的創新型小分子偶聯化學藥物,擬用於治療肌萎縮側索硬化(ALS)。肌萎縮側索硬化(ALS),又稱“漸凍症”,是一種神經系統退行性疾病,影響大腦運動皮層、腦幹和脊髓的運動神經元細胞羣,導致肌肉失去神經支配。HLX99具有多重藥理學特性,可能通過包括抗氧化能力和調節炎症反應等神經保護作用治療肌萎縮側索硬化症(ALS)。臨牀前動物藥效模型表明,HLX99在肌萎縮側索硬化(ALS)動物模型中顯示出療效,且具有良好的安全性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account